Showing results (71-80 of 3,654) with videos related to

Sort By:
Pageof 366
Breast Cancer Research : BCR|May 25, 2012
Die and let live: harnessing BikDD to combat breast cancer stem cellsMario Giuliano, Meghana V Trivedi, Rachel Schiff
Breast Cancer Research : BCR|May 25, 2012
Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomyLaura S Dominici, Elizabeth A Mittendorf, Xumei Wang, et al.
Breast Cancer Research : BCR|May 25, 2012
CD44 enhances invasion of basal-like breast cancer cells by upregulating serine protease and collagen-degrading enzymatic expression and activityNicola Montgomery, Ashleigh Hill, Suzanne McFarlane, et al.
Breast Cancer Research : BCR|September 18, 2015
Erratum to: Humanization of the mouse mammary gland by replacement of the luminal layer with genetically engineered preneoplastic human cellsStephanie Verbeke, Elodie Richard, Elodie Monceau, et al.
Breast Cancer Research : BCR|September 19, 2015
Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasionHanan S Elsarraj, Yan Hong, Kelli E Valdez, et al.
Breast Cancer Research : BCR|May 29, 2016
Intermittent energy restriction induces changes in breast gene expression and systemic metabolismMichelle N Harvie, Andrew H Sims, Mary Pegington, et al.
Breast Cancer Research : BCR|May 29, 2016
Germline APOBEC3B deletion is associated with breast cancer risk in an Asian multi-ethnic cohort and with immune cell presentationWei Xiong Wen, Jaslyn Sian-Siu Soo, Pui Yoke Kwan, et al.
Breast Cancer Research : BCR|June 2, 2016
Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancerNikiana Simigdala, Qiong Gao, Sunil Pancholi, et al.
Breast Cancer Research : BCR|April 7, 2016
Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibitionCedric Leroy, Pedro Ramos, Karen Cornille, et al.
Breast Cancer Research : BCR|May 13, 2016
Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancersMichael J Gray, Jian Gong, Michaela M S Hatch, et al.
Pageof 366